Taken together these data highlight a correlation between cyclin D1/CDK4 expression and KRAS mutation in lung ADC, suggesting enhanced activation of CDK4/Cyclin D in KRAS mutant lung cancer. The gene discussed is KRAS; the disease is lung cancer.